PDMR Dealings / Market Share Sale
PDMR Dealings / Market Share Sale
Oxford, UK - 10 August 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 07 August 2018 Jason Slingsby, Chief Business Officer, exercised 5,334 options at 487.4p, exercised 7,139 options at 490.0p and 6,155 options at 487.4p and sold all of the resulting shares at 890.1p.
Following this transaction he holds 68,929 options and no shares in the company.
The issued share capital of the Company is 65,752,788 ordinary shares of 50 pence each.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||||||
|
a) |
Name |
Jason Slingsby |
||||||||
|
2. |
Reason for the notification |
|||||||||
|
a) |
Position/status |
Chief Business Officer
|
||||||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||||||
|
3. |
Details of the Issuer |
|||||||||
|
a) |
Name |
Oxford BioMedica plc |
||||||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||||||
|
b) |
Nature of the transaction |
Exercise of options |
||||||||
|
c) |
Currency |
GBP - British pound |
||||||||
|
d) |
Price(s) and volumes(s) |
|
||||||||
|
e) |
Aggregated information - Aggregate volume
- Price
- Aggregated total
|
18,628
£4.884
£90,978.49 |
||||||||
|
f) |
Date of the transaction |
2018-08-07 |
||||||||
|
g) |
Place of the transaction |
London Stock Exchange, Main Market (XLON) |
||||||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Jason Slingsby |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Business Officer
|
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford BioMedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Disposal |
||||
|
c) |
Currency |
GBP - British pound |
||||
|
d) |
Price(s) and volumes(s) |
|
||||
|
e) |
Aggregated information - Aggregate volume
- Price
- Aggregated total
|
18,628
£8.901093
£165,809.56 |
||||
|
f) |
Date of the transaction |
2018-08-07 |
||||
|
g) |
Place of the transaction |
London Stock Exchange, Main Market (XLON) |
||||
-Ends-
|
For further information, please contact: |
|
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
|
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
|
Tel: +44 (0)20 3709 5700 |
Notes for editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund